Studying communicable diseases often involves logistical and safety challenges. Researchers must collect reliable blood samples from diverse populations, sometimes in remote or resource-limited areas. Dried blood spot (DBS) testing offers an elegant solution. With just a finger-prick and a filter paper card, DBS makes large-scale disease surveillance, outbreak investigation, and long-term monitoring more accessible, safe, and cost-effective. This technology is increasingly recognized by public health agencies as a critical tool in infectious disease research.
One of DBS’s greatest advantages is accessibility. Collecting venous blood requires skilled phlebotomists and proper storage conditions — resources that are not always available in rural or underserved regions. By contrast, DBS collection requires only a lancet and filter card. Community health workers or even patients themselves can collect samples, which are then mailed to central laboratories.
DBS samples remain stable at room temperature for extended periods, eliminating the need for refrigeration or freezing during transport. This stability is crucial when studying infectious diseases in tropical climates or during outbreaks in remote areas. Whether mailed across countries or carried by field workers, DBS cards arrive at laboratories ready for reliable testing, including sensitive analyses such as PCR for viral RNA or immunoassays for antibody detection.
Handling liquid blood samples requires stringent biosafety precautions. DBS mitigates many of these risks because the drying process reduces viability of many pathogens, thereby lowering biosafety risks during storage and transport. Unlike vials of blood, DBS cards are small, lightweight, and durable, making them easier to package and transport. For large-scale surveys, thousands of DBS cards can be handled and shipped without the complications of managing liquid specimens.
DBS samples can be used for various laboratory tests relevant to communicable disease studies. They are compatible with immunoassays for antibody detection, antigen tests, and molecular assays such as PCR. A single DBS card may even support multiple tests, enabling simultaneous screening for infections such as HIV, hepatitis, and syphilis. While sensitivity can be slightly lower than plasma testing due to reduced sample volume, methodological improvements continue to close this gap.
Real-world applications of DBS highlight its value. In Scotland, outreach programs used DBS to test for hepatitis C among people who inject drugs, dramatically increasing case detection rates. DBS has also supported large-scale seroprevalence studies for measles, malaria, and COVID-19, providing insights into immunity levels and disease spread. In sub-Saharan Africa, DBS is widely used for HIV viral load monitoring, giving clinicians and patients in remote areas access to essential treatment guidance.
DBS technology has proven particularly valuable in engaging populations that face barriers to traditional healthcare, such as people who use drugs, sex workers, or residents of conflict zones. Because DBS requires only a finger-prick, individuals are more willing to participate in testing. Self-sampling models, where DBS kits are mailed directly to individuals for at-home collection, further enhance access while preserving privacy.
Dry blood spot tests can enhance the way communicable disease research and surveillance are conducted. Its combination of accessibility, stability, and safety makes it a vital tool for expanding the reach of public health programs. By enabling sample collection in places where traditional methods fail, DBS empowers researchers to gather critical data on disease transmission, immunity, and treatment outcomes. At RDA Spot, our DBS kits are designed to support this mission, helping advance infectious disease monitoring and global health.
References